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Objective. This study investigates the oncogenic role ofWWP1, an ubiquitin ligase linked to tumor promotion, in oral cancer.
Study design. An array-based comparative genomic hybridization was used to detect chromosomal changes in 10 oral cancer
specimens. An additional 59 specimens and 6 cultured oral cancer cells were further examined to evaluate changes in the
DNA copy number and messenger RNA (mRNA) and protein expression of WWP1.
Results. The copy number of theWWP1 gene and its mRNA levels were significantly increased in the oral cancer specimens.
An elevated WWP1 gene expression was observed in 6 cultured oral cancer cell lines. Knockdown of the endogenous
WWP1 using small hairpin RNA further showed that deficiency ofWWP1 suppressed cell growth and caused apoptosis in oral
cancer cells.
Conclusion. Our results reveal thatWWP1might play an oncogenic role in oral cancer cells. (Oral Surg Oral Med Oral Pathol
Oral Radiol 2013;116:221-231)Oral cancer is among the most prevalent malignancies
worldwide.1 Predictions by the World Health Organiza-
tion indicate a continual rise of oral cancer in the decades
to come. A sharp increase in the incidence of oral cancer
has been observed in Denmark, France, Germany,
Scotland, and Central and Eastern Europe.2 Additionally,
the mortality and morbidity of oral cancer have increased
annually in Asia. Factors involved in the etiology of oral
cancer in Western countries include sunlight over-
exposure, smoking, and alcohol consumption. In
contrast, the use of areca or betel nut in many cultures
appears to be a major etiological factor in Asia.
Carcinogens known to be involved in the develop-
ment of oral cancer include polycyclic aromatic
hydrocarbons, N-nitrosamine and aromatic amines from
tobacco, acetaldehyde from metabolizing alcohol, and
arecoline from areca, which have been shown to cause
chromosomal aberrations including insertion, deletion,
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inhibition, and the abnormal regulation of cell cycle-
related genes have all been shown to play roles in the
development of oral cancer. These alterations could
affect the epithelial cell behavior through the loss of
chromosomal heterozygosity, resulting in the progres-
sion to invasive squamous cell carcinoma.4,5
Change in DNA copy number is a common genetic
alteration in tumors. Genome-wide analysis using
comparative genomic hybridization (CGH) has shown
common ampliﬁcation in chromosomes 3q, 8q, 9q, 11q,
and 20q in oral cancer. Conversely, 4q, 3p, 5q, 15q, and
18q are areas of frequent deletion.6-11 It has been shown
that ampliﬁcation in the 11q13 region correlates with
transformation of oral preneoplastic lesions to carcinoma
in situ, whereas the deletion in chromosomes 4q, 8p21-
23, and 18q is linked to the progression from carcinoma
in situ to oral squamous cell carcinoma (OSCC).12-14
However, the underlying mechanisms of these mutations
in oral cancer remain largely unexplored.
The ubiquitin proteasome pathway (UPP)-mediated
protein degradation is a highly regulated process
implicated in cell proliferation, differentiation, and
carcinogenesis. The role of E3 ubiquitin ligases in
regulating the stability of many cell cycle proteins is
well established; the disruption of the components
involved in the machinery could lead to the abnormal
growth of cells. Studies suggest that E3 ligases areStatement of Clinical Relevance
Our ﬁndings provide a new interference target for
oral cancer since WWP1 is overexpressed in clinical
oral cancer specimen and knockdown of WWP1
gene in oral cancer cell line can cause apoptosis.
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222 Lin et al. August 2013oncogenic because they target tumor suppressors such
as p53 for degradation.15 The WW domain containing
E3 ubiquitin protein ligase 1 (WWP1) contains 4
tandem WW domains and a homologous E6AP
carboxy-terminus (HECT) region. It has previously
been reported that the overexpression of WWP1
promotes cell growth, whereas its depletion suppresses
proliferation and induces the apoptosis of breast cancer
cells.16 The growth promoting function of WWP1 has
also been observed in other cell types, including
MDCK canine kidney epithelial cells, PC-3 prostate
cancer cells, and HCT116 colon cancer cells.17-19
Deﬁciency of WWP1 in HCT116 cells has been shown
to sensitize cells to chemotherapeutic drugs, such as
doxorubicin and cisplatin.19 In this study, we have
shown that the copy number of the WWP1 gene and its
messenger RNA (mRNA) levels are signiﬁcantly
increased in tissues from patients with oral cancers. In
addition, we further demonstrate that the depletion of
WWP1 in cultured oral cancer cells inhibits cell
proliferation and induces apoptosis. This study suggests
a potential oncogenic role for WWP1 in oral cancers.MATERIALS AND METHODS
Patients and clinicopathological data
Oral tissue specimens for array CGH assays were ob-
tained from 10 patients who received surgical resection at
China Medical University Hospital (Taichung, Taiwan,
Republic of China) in 2009. The clinicopathological data
of the patients are shown in Table I. Additional 59 tissue
specimens were collected from oral squamous cell
carcinoma patients who underwent primary surgical
resection at the same hospital between 2009 and 2010;
the ages of these patients ranged between 26 and 77 years
(average 50.6 years). Clinicopathological information,
obtained retrospectively from medical records, included
primary tumor size, nodal status, histological grade, and
the presence of tumor necrosis and perineural or vascularTable I. Clinicopathologic characteristics of oral cancer pat
ID Age Sex Site Smoking A
1 52 M Buccal Yes Y
2 45 M Buccal Yes Y
3 38 M Tongue Yes Y
4 44 M Retromolar Yes Y
5 61 M Tongue Yes Y
6 53 M Buccal Yes Y
7 54 M Buccal Yes Y
8 40 M Buccal Yes Y
9 58 M Oropharynx Yes Y
10 45 M Tongue Yes Y
Tumor size: T1, <20 mm; T2, 20-40 mm; T3, 40-60 mm. Lymph node in
a single ipsilateral lymph node (<30 mm); N2a, metastasis in a single ipsil
lymph node involvement (<60 mm). Distant metastases: M0, no distant me
T1N0M0; II, T2N0M0; III, T3N0M0 or T1/T2/T3N1M0; IVA, Tl/T2/T3N2invasion. This study was conducted with approval from
the Ethics and Clinical Research Committee of China
Medical University. Informed consent was obtained from
all patients or their legal guardians.
Cell culture
The OSCC cell lines, including Ca922,20 SAS,21 and
HSC-322 (obtained from Japanese Collection of Research
Bioresources, Tokyo, Japan) and CAL2723 (fromATCC)
are frequently used model systems for OSCC. OECM-1
provided by Dr. Kuo-Wei Chang.24 TW206, which was
cloned from a betel nut chewing oral cancer patient in
Taiwan, was from Dr. Pei-Jung Lu (National Cheng
Kung University, Taiwan). All cell lines were maintained
and passaged according to the guidelines provided by the
cell banks. The Ca922 cells were cultured in MEM
(Invitrogen, Carlsbad, CA, USA), SAS, HSC-3, TW206,
and CAL27 cells were cultured in DMEM (Invitrogen),
OECM-1 cells were cultured in RPMI-1640 (Life Tech.,
Gaithersburg, MD, USA), supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco, Grand
Island, NY, USA), penicillin (100 U/mL; Gibco) and
streptomycin (100 mg/mL; Gibco). Cells were cultured at
37 C in an atmosphere of 5% CO2.
Array-based comparative genomic hybridization
(aCGH) assay
Ten pairs of human oral cancer samples and the adjacent
morphologically normal tissues were analyzed by aCGH
using the Human Genome CGH Microarray Kit 244 A
(Agilent Technologies, Santa Clara, CA, USA), which
detects more than 236,000 coding and noncoding human
genes. The probes used were according to the instruc-
tions of National Center for Biotechnology Information
(NCBI) build 36. The results were analyzed by CGH
Analytics 3.4.40 software, and statistical signiﬁcance
was examined by Student’s t test (P < .05 indicates
signiﬁcant difference). The ADM-2 algorithm was usedients
reca TNM Clinical stage Differentiation
es T2N1M0 III Moderate
es T3N2aM0 IVA Well
es T2N0M0 II Well
es T2N1M0 III Well
es T2N2aM0 IVA Well
es T3N1M0 III Well
es T2N0M0 II Well
es T2N2bM0 IVA Moderate
es T2N0M0 II Well
es T1N2bM0 IVA Well
volvement: N0, no regional lymph node metastases; N1, metastasis in
ateral lymph node (>30 mm and <60 mm); N2b, multiple ipsilateral
tastases; M1, clinical evidence of distant metastases. Clinical stage: I,
M0 or T4a, any N and MO; IVC, any T, any N and M1.
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genomic regions.
DNA extraction
The tissues from oral cancer patients were removed from
liquid nitrogen and ground into powder, DNA was ex-
tracted using the QIAamp DNAMini Kit (Qiagen, Hilden,
Germany) according to the manufacture’s instructions.Annexin V-FITC binding assay
Apoptosis was detected by annexin V-FITC (ﬂuores-
cein isothiocyanate) binding assay. Normal, early
apoptotic, late apoptosis, and necrotic cells were dis-
cerned using the annexin V-propidium iodide (PI)
kit according to the manufacturer’s instructions (BD
Pharmingen, San Diego, CA, USA). After washing in
PBS, the cells were resuspended for 10 min in the
staining solution and analyzed by ﬂow cytometry. At
least 100,000 cells were analyzed for each sample to
calculate the percentages of viable and dead cells.Real time reverse transcription-polymerase chain
reaction (RT-PCR)
Total tissue RNA was extracted using RNeasy Mini Kit
(Qiagen) following the manufacturer’s instructions. The
ﬁrst-strand complementary DNA was synthesized with
the NCode miRNA kit using 2 mg of RNA according to
the manufacturer’s protocol (Invitrogen). PCR ampliﬁ-
cation was performed using the Sequence Detection
System (ABI PRISM 7900HT Sequence Detection
System, Foster City, CA, USA) with speciﬁc primers.
For WWP1 gene expression, the forward primer used is
50-GGAGCTATGCAACAGTTTAACCAA-30, and the
backward primer is 50-AAGTAAACCCTGTCTGTT
GAATCCA-30. Relative gene expression was analyzed
using the 2DDCt method.25Immunohistochemistry
Following routine processing as previously described,26
tissue sections were incubated with anti-WWP1 antibody
at a dilution of 1:50 at 4 C overnight in a humid chamber.
The identical tissue array incubated with pre-immune
rabbit IgG (Cat# PP64; Millipore Corp., Billerica, MA,
USA) was used as a negative control. The extent of
immunoreactivity was scored based on the percentage of
positive cells found in each tissue section: <10%, absent
(); 10%-50%, weak (þ); and >50%, strong (þþ).26Immunoblot analysis
Cells were lysed in buffer (150 mM NaCl, 50 mM Tris,
1 mM EDTA, and 0.02% NaN3) containing 1% NP40
and protease inhibitors (Roche, Indianapolis, IN, USA)
for 30 min on ice. The lysates were centrifuged at13,000 rpm for 30 min at 4 C. Protein concentration
was determined by the Bradford assay kit (Bio-Rad,
Hercules, CA, USA). Approximately 40 mg of lysates
were separated by SDS polyacrylamide gel electropho-
resis, and analyzed by immunoblotting using speciﬁc
antibodies for WWP1 (Abcam, Cambridge, MA, USA)
and actin (Millipore Corporation, Billerica, MA, USA).Flow cytometry
Cells (1  106) were ﬁxed in ice-cold 70% ethanol
at 4 C for 16 h. The cells were then treated with RNAase
A (1 mg/mL) and stained with propidium iodide (20 mg/
mL) for 30 min. Cells were analyzed by ﬂow cytometry
using FACScan system (BD Biosciences, San Jose, CA,
USA), and data were processed with WinMDI software
(The Scripps Research Institute, La Jolla, CA, USA).Plasmid construction and viral infection
An shRNA expression system [The RNAi Consor-
tium (TRC)] was used to knockdown gene expres-
sion of WWP1. Two pLKO.1-shRNA constructs:
WWP1 sh-1 (TRCN0000003395) and WWP1 sh-2
(TRCN0000003397), were obtained from the
National RNAi Core Facility, Academia Sinica, Tai-
pei, Taiwan. Production of lentivirus and lentiviral-
mediated infection were performed according to the
protocols provided by TRC.
RESULTS
WWP1 is frequently amplified and overexpressed
in oral cancers
Array CGH assays were performed on tumor specimens
and adjacent non-neoplastic tongue tissues from 10 oral
cancer patients. The study subjects were all men, aged
from 38 to 61 years and clinically were stage 2 or higher
(Table I). As shown in Figure 1A, broad ampliﬁcation
regions could be detected at chromosomes 1p, 3q, 7p,
8q, 9, 11q, 16, 17, 19, 20, and 22, whereas the deletion
regions were found in chromosomes 3p, 4q, 5q, 8p, 10,
18q, and Y. Because WWP1 resides at 8q21, which
frequently mutates in breast and prostate cancers, we
examined whether the WWP1 gene undergoes genomic
ampliﬁcation in oral cancer. As shown by the array CGH
results, 8 out of 10 clinical oral cancer samples exhibited
a WWP1 gene ampliﬁcation (Figure 1B). To verify the
array CGH results in a larger number of clinical speci-
mens,WWP1DNA levels were examined using real time
PCR in 59 pairs of oral cancer tumors and their non-
neoplastic counterparts. As shown in Figure 2A, when
compared with the corresponding non-neoplastic coun-
terparts, 39% (23/59) of oral cancer samples exhibited an
approximately 1.5-fold increase in WWP1 DNA levels
(average value: 1.46 0.66), whereas only 2% (1/59) of
the samples showed more than a 50% decrease in
Fig. 1. Array CGH analysis showing fold changes of chromosomes and the WWP1 gene in clinical oral cancer specimens. (A)
Array CGH was performed on 10 oral cancer tissue specimens; the ratios between tumor and their non-neoplastic counterparts were
calculated as fold changes. The regions ampliﬁed in the indicated chromosomes (A) and 8q21 harboring the WWP1 gene (B) are
shown in red, and areas with chromosome deletions are shown in green. Student’s t test for statistical signiﬁcance reveals P < .05.
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Fig. 2. Changes of WWP1 gene copy number and mRNA expression in clinical oral cancer specimens. (A) Real time PCR was
performed on DNA from 59 oral cancer specimens and their non-neoplastic counterparts; the expression of ATP2B4 served as an
internal control. (B) Real time RT-PCR ampliﬁcations were performed on RNA prepared from 41 oral cancer specimens and their
corresponding non-neoplastic counterparts for WWP1 gene expression. Ratios between tumors and their non-neoplastic counter-
parts in (A) and (B) are calculated as fold changes. The signiﬁcance of the correlation between incidence of the high WWP1 copy
number in oral cancer specimen was analyzed using Student’s t test which indicates P < .001. (C) WWP1 expression in
a representative oral cancer tissue. Tissue sections were subjected to immunohistochemistry assay using anti-WWP1 antibodies.
The WWP1 positive cells showed dark red in color.
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WWP1 gene seems to have no direct link to the clini-
copathological characteristics of oral cancer patients, we
have found an inverse correlation between the ampliﬁ-
cation and expression of WWP1 and the differentiationstage of the oral cancer cells. We also analyzed the
mutations in the coding region of the WWP1 gene. As
shown in Table II, the mutations of WWP1 in OSCC
tumors include single base substitutions, A/G or C/T
transitions, and A/T or C/G transversions. Real time
Table II. WWP1 sequence analysis of 40 oral cancer
specimens
Exon
Allele
change
Total
number
Mutation
number
Mutation
percent
Exon l2-13-14 C/ A 25 4 0.16
Exon 18 T/ A 29 3 0.1034
Exon 18 T/ A 20 2 0.1
Exon 21 T/ A 82 36 0.439
Exon 18 T/ A 20 2 0.1
Exon 25 T/ A 35 9 0.2571
Exon 2l C/ A 82 37 0.4512
Exon 21 T/ G 44 13 0.2955
Exon 23-24 G/ C 50 7 0.14
Exon 4-5 T/ A 49 1 0.0204
Exon 4-5 T/ A 44 18 0.4091
Exon 4-5 T/ A 4 1 0.25
Exon 8 T/ G 41 29 0.7073
Exon 11 T/ A 22 6 0.2727
Exon 11 T/ A 28 3 0.1071
Exon 11 T/ A 15 4 0.2667
Exon 11 T/ G 57 13 0.2281
Exon 11 T/ C 57 13 0.2281
Exon 12-13-14 T/ C 25 15 0.6
Exon 12-13-14 G/ A 3 1 0.3333
Exon 15-16 T/ C 50 1 0.02
Exon 15-16 G/ A 50 1 0.02
Exon 17 T/ C 26 22 0.8462
Exon 2 T/ C 48 7 0.1458
Exon 21 G/ A 82 2 0.0244
Exon 21 G/ A 82 8 0.0976
Exon 21 T/ C 82 37 0.4512
Exon 21 G/ A 82 26 0.3171
Exon 22 T/ C 5 1 0.2
Exon 23-24 T/ C 50 33 0.66
Exon 23-24 T/ C 49 1 0.0204
Exon 25 G/ A 49 1 0.0204
Exon 25 T/ C 43 2 0.0465
Exon 25 G/ A 46 41 0.8913
Exon 3 G/ A 50 22 0.44
Exon 3 T/ C 50 2 0.04
Exon 3 G/ A 50 6 0.12
Exon 4-5 T/ C 15 6 0.4
Exon 4-5 T/ C 15 6 0.4
Exon 9 T/ C 49 1 0.0204
Table III. Associations between clinicopathological
parameters and WWP1 mRNA expression in 46 oral
cancer specimens
Clinical
information P value
WWP1 mRNA expression fold
1.5 <1.5
Age
>50 6 13
50 10 17
.76
Tumor size
I-II 12 19
III-IV 4 11
.32
Lymph node metastases
N ¼ 0 13 20
N  1 3 10
.24
Stage
I-II 10 15
III-IV 6 15
.30
Differentiation
Poor-moderate 11 10
Well 4 19
.02*
*Indicates statistical signiﬁcance by Fisher’s exact test.
Table IV. Comparison of WWP1 proteins expression
between normal and cancer specimens
Normal
(%) Tumor (%) Age T N M Stage Differentiation
0.0 () 0.0 () 48 1 0 0 1 Moderate
15.6 (þ) 53.6 (þþ) 76 2 0 0 2 Well
0.0 () 0.0 () 55 3 0 0 3 Moderate
27.6 (þ) 39.9 (þ) 73 2 1 0 3 Moderate
0.0 () 35.9 (þ) 34 2 1 0 3 Moderate
8.1 () 0.0 () 42 4A 2 0 4A Well
0.0 () 0.0 () 68 4A 0 0 4A Well
The scoring principle has been described in Materials and methods.
The stage assessment is based on TNM (tumorenodeemetastasis)
staging system.27
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WWP1 mRNA expression had increased. As shown in
Figure 2B, the abundance ofWWP1mRNAwas elevated
in approximately 35% (14/46) and reduced in 22% (10/
46) of the tumor specimens analyzed, relative to their
non-neoplastic counterparts. However, 12 out of the 14
high WWP1 mRNA expressing specimens exhibited
increased WWP1 DNA levels, whereas only 1 out of 10
low WWP1 mRNA expressing specimens showed
increased WWP1 DNA levels. A correlation between
WWP1 mRNA expression and the degree of tumor
differentiation was found (Table III). Analysis of 7 cases
of oral cancer specimens and their non-neoplastic
counterparts using immunohistochemistry further indi-
cated an enhanced WWP1 protein staining in the tumor(Figure 2C, Table IV). WWP1 protein is expressed in
both the nucleus and the cytoplasm, and tends to be
present in cells with higher nucleo-cytoplasmic ratios.
Together, these results show that the WWP1 gene is
ampliﬁed and overexpressed in oral cancer cells.Increased DNA copy number and mRNA
expression of WWP1 in oral cancer cell lines
Following the array CGH assays, we assessed whether
the WWP1 gene is ampliﬁed and overexpressed in
cultured OSCC cells, including HSC3, CA922, CAL27,
TW206, SAS, and OECM-1. As shown by the results of
real time RT-PCR in Figure 3A and B, these OSCC cells
Fig. 3. Levels of WWP1 DNA and mRNA in oral cancer cell lines. (A) Real time PCR ampliﬁcations were performed on DNA
extracted from the indicated oral cancer cell lines and HFK was used as a control. Amounts of ATP2B4 DNA were used as an
internal control for detecting copy number. (B) Real time RT-PCR ampliﬁcations were performed on RNAs prepared from the cells
for WWP1 mRNA expression. The results were normalized to GAPDH (glyceraldehyde 3-phosphate dehydrogenase). The ratios
obtained in (A) and (B) were normalized to that obtained from HFK. (C) The expression of WWP1 protein in oral cancer cell lines
was examined through immunoblotting using a speciﬁc antibody for WWP1. Actin was shown as a normalization control.
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compared with control human foreskin keratinocytes
(HFKs).28 Among the cell lines, TW206 and OECM-1were established from OSCC patients in Taiwan who
were habitual betel nut users. The WWP1 mRNA levels
in these 2 locally established cell clones were
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cells, and signiﬁcantly higher than the rest of the OSCC
cell lines analyzed. In accordance with the increased
mRNA expression, immunoblot analysis showed
elevated WWP1 protein levels in these 2 cell lines
(Figure 3C). The ﬁnding that WWP1 is overexpressed in
oral cancer tissues and cultured OSCC cells suggests an
oncogenic role of WWP1 in oral cancer.Fig. 4. Effective knockdown of WWP1 mRNA and protein
expression using shRNAs in OECM-1 cells. The OECM cells
were infected with a lentivirus-mediated vector containing
shRNAs (WWP1 sh1 and sh2) or an empty vector (control).
Effective knockdown was shown using WWP1 mRNA
expression determined by real time RT-PCR ampliﬁcation (A)Knockdown ofWWP1 suppresses cell proliferation
and induces apoptosis of OECM-1 cells
We examined the functional signiﬁcance of the
endogenous WWP1 gene using cultured OSCC cells.
The expression of WWP1 was knocked down using
2 speciﬁc shRNAs in OECM-1 cells. As shown in
Figure 4, WWP1 mRNA and protein levels were
effectively suppressed. Trypan blue exclusion assays
showed that the depletion of WWP1 by either shRNA
could signiﬁcantly inhibit the proliferation of OECM-1
cells (Figure 5A). Similar results of growth inhibition
by WWP1 shRNA could be observed in other OSCC
cells, TW206 (data not shown). Flow cytometry anal-
ysis showed that the depletion of WWP1 resulted in
a signiﬁcant cell population increase during the subG1
phase (Figure 5B). In addition, Annexin V staining
analysis indicated that the depletion of WWP1 induced
apoptosis in the OECM-1 cells (Figure 5C). These
results suggest an anti-apoptotic role of WWP1 in oral
cancer cells.andWWP1 protein expression examined using immunoblotting
(B). The quantitative results normalized to GAPDH are shown.DISCUSSION
In this study, we have provided evidence suggesting that
WWP1 E3 ubiquitin ligase has an oncogenic role in oral
cancer. Previous studies have demonstrated that chro-
mosome 8q21, in which WWP1 resides, is a frequently
ampliﬁed chromosome region in oral cancer.7-12 Consis-
tent with this ﬁnding, our array CGH analysis on 10 pairs
of oral cancer samples revealed a large range of gene
ampliﬁcation within chromosome 8q. Analysis using real
time PCR ampliﬁcations in tissues from 59 OSCC
patients veriﬁed that WWP1 is ampliﬁed in OSCC. In
addition, we showed thatWWP1mRNA is overexpressed
in clinical cancer samples and cultured oral cancer cells.
Our ﬁndings of large ampliﬁcation regions in chro-
mosomes 3q, 8q, 9, 11q, and 20, and deletions in the
regions of chromosomes 3p, 4q, 5q, and 18q are consis-
tent with the results reported by others.7-11 However, our
array CGH results on the ampliﬁcation in chromosome 16
have not been documented. Because all patients in the
present study were habitual betel nut users, one can
assume that the OSCC-causing mutagens in these
patients might derive from betel nut, and that they should
be distinguished from the oral cancer causing agents in
Western countries. In this regard, among the 6 cell linesanalyzed, the copy number of the WWP1 gene and the
mRNA levels are highest in TW206 and OECM-1, the 2
cell lines cloned from patients that chew betel nuts.
However, the other 4 cell lines exhibited a lower increase
or no signiﬁcant increase, suggesting a relationship
between betel nut use and WWP1 gene overexpression.
According to the real time PCR results from 59 pairs
of oral cancer samples, the WWP1 gene is ampliﬁed in
39% (23/59) of the tumors. The ratio is similar to the
results obtained from prostate and breast cancer spec-
imens.16,18 We also found an inverse correlation be-
tween the ampliﬁcation and expression of the WWP1
gene and the differentiation stage of the oral cancer
cells. However, the expression of the WWP1 gene
seems to have no direct link to clinicopathological
characteristics. The link of oral cancer differentiation to
its keratinization level warrants further investigation.
In addition to gene ampliﬁcation, we noticed that a low
percentage of OSCC specimens exhibited WWP1 gene
mutations, including a single base substitution, A/G or
C/T transitions, and A/T or C/G transversions. Both
changes were heterozygous and were not reported in
the single nucleotide polymorphisms database at the
Fig. 5. Deﬁciency of WWP1 suppresses cell growth and induces apoptosis in OECM-1 cells. The expression of WWP1 was
knocked down separately using 2 WWP1 shRNAs or a control vector in OECM-1 cells, as shown in Figure 4. (A) The viability of
cells was determined for 3 consecutive days using the trypan blue exclusion assay. The data shown are the mean  standard error
from 3 independent experiments (upper panel). A representative picture taken under a light microscope on day 3 is shown (lower
panel). (B) The WWP1 knockdown and control cells were ﬁxed and stained with PI, and analyzed using ﬂow cytometry for the
percentage of cells in each phase of the cell cycle. The data were analyzed using Student’s t test for statistical signiﬁcance. The stars
indicate P < .05. (C) Control and WWP1 knockdown cells were ﬁxed and stained with annexin V and PI. The data shown are
representative of 3 independent experiments. The percentage of apoptotic cells is presented.
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cancer study.18
Our preliminary results showed that the WWP1
protein is distributed in both the nucleus and the cyto-
plasm, and is more likely to express in cells with higher
nuclear-to-cytoplasmic ratios, suggesting that the
subcellular distribution of WWP1 might affect cancer
cell phenotypes. Nguyen et al.29 have shown that the
expression of WWP1 protein in breast cancer correlates
to prognosis. In contrast to the patients that expressed
WWP1 primarily in the cytosol, the patients with no
detectable WWP1 in the cytosol tended to have a poorer
prognosis. Accordingly, the prognosis of patients with
both nuclear and cytosolic WWP1 expression was fair.
We have demonstrated that knockdown of WWP1 in
cultured oral cancer cells resulted in growth suppression
(Figure 5A and our unpublished data on TW206 cells)
in part through apoptosis induction. The inhibition of
apoptosis of breast and prostate cancer cells by WWP1
through the inhibition of TGF-b-mediated signaling has
been reported.30 In addition, it has been shown that
WWP1 regulates the activity of p53 and KLF2 and
affects cancer cell proliferation by modulating the
protein degradation system.31,32 However, the oral
cancer cell lines used in the present study were unre-
sponsive to TGF-b treatment (data not shown), sug-
gesting that a TGF-b independent pathway is involved
in the WWP1-mediated activation of cell proliferation.
In summary, we have shown that the WWP1 gene is
ampliﬁed and overexpressed in oral cancer specimens.
In addition, we have demonstrated that deﬁciency of
WWP1 results in increased apoptosis in cultured oral
cancer cells. These ﬁndings provide new insights in
developing therapeutic interference for oral cancer.
We thank the Tissue-bank of China Medical University
Hospital for technical assistance and Dr. Guan-Chin Tseng
(China Medical University Hospital) for the pathology
assessment of tissue sections in this study.
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